ÐÓ°ÉÔ­´´

ReViral, based in London, offers a strong business opportunity in antiviral treatments. As a biotech firm, it focuses on innovative antiviral solutions to address the ongoing issue of viral infections. By targeting health tech and pharma sectors, ReViral aims to develop cutting-edge treatments that could reduce morbidity and mortality rates. Operating on a B2B model, the company collaborates with other businesses rather than selling directly to consumers. With backing from investors like Novo A/S and Andera Partners, ReViral is well-positioned to advance its research and bring new antiviral treatments to market. Its commitment to innovation sets it apart from existing antiviral medications and vaccines.